The Number of Cancer Survivors Is Projected To Increase to 22.2 Million By 2030 Fostering Oncology Drug Pipeline Analysis Market
North
America is estimated to dominate the global oncology drug pipeline analysis
market in the near future and this is attributed to the high prevalence of
cancer and increasing launch of various novel drugs with improved efficacy.
According to the National Cancer Institute, as of January 2019, there were an
estimated 16.9 million cancer survivors in the United States. The number of
cancer survivors is projected to increase to 22.2 million by 2030.
The
oncology field is experiencing significant growth and this is attributed to the
increasing development of various novel therapies for the treatment of cancer. For
instance, in February 2021, Rhizen Pharmaceuticals AG, a clinical-stage,
oncology-focused biopharma company, with a 50% stake owned by Alembic Pharmaceuticals
and the rest by its Indian CEO Swaroop Vakkalanka, has announced that its the novel, next-generation PI3K-delta inhibitor Umbralisib (Ukoniq) has secured
U.S. FDA accelerated approval for the treatment of blood cancer. Again in
September 2020, a Blueprint Medicines corporation has received FDA approval for
cancer drug, making it the latest targeted therapy. Thus, rising such approvals
for cancers therapies is propelling the growth of the oncology
drug pipeline analysis market.
1. In April 2019, Sun Pharmaceutical Industries
announced the launch of INFUGEM injection, used for the treatment of cancer, in
the US market. In July 2018, Sun Pharma had received approval from the US
health regulator for INFUGEM injection
2. In October 2020, AstraZeneca Pharma India Ltd. the
launch its Acalabrutinib 100 milligram capsules, used for the treatment of
various types of blood cancers, under the brand name 'Calquence'
An
oncology drug pipeline analysis is a specialized form of medical research done
on human cancer cells. It consists of a high- magnification examination of
cancer cells under the microscope, concentrating on their properties such as
proliferation, invasion, differentiation, metastasis, and resistance to
therapy. A unique feature of oncology pipelines is that they concentrate on
oncologist preoperative and postoperative clinical studies in order to
establish management of patients with oncology disease. This form of analysis
has revolutionized Oncology and is used to improve oncology service delivery.
Due to the advancement in analytical techniques and increased use of advanced
imaging technologies, Oncology pipelines are now a key component of oncology
research. Oncology is one of the fastest-growing cancer specialties in the
world with tremendous growth potential in both the public and private markets.
Comments
Post a Comment